YahooOctober 26, 2026 at 1:30 PM NYYesterday
Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027
In the 776-patient Phase 3 trial, Sac-TMT-treated patients had a median overall survival of 19 months compared to 12.1 months for chemotherapy
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
